Conversely, the association between high PLK1 expression and an immunosuppressive tumor microenvironment, as demonstrated in our data, suggests that PLK1 inhibitors might synergize with immunotherapies in immune-“cold” subtypes, such as those with STK11 mutations. This evidence concerns the gene STK11 and neoplasm.